Global

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology
New Phase IIb results for AstraZeneca’s oral GLP-1 candidate elecoglipron suggest the company is positioning itself as a future competitor in obesity and cardiometabolic disease. While Novo Nordisk and Eli Lilly continue to dominate the market, AstraZeneca’s latest data highlight growing competition in one of healthcare’s fastest-growing therapeutic areas.

Pancreatic Cancer Finally Gets a RAS Moment

The invisible heart disease crisis: Why congenital heart disease is moving up the global health agenda

Cancer Sequencing Becomes the Operating System of Precision Oncology

Prostate Cancer Value Starts Counting Cognition

The ASCO Drug Race Still Runs Through Genomic Testing

High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts

WHO’s New AMR Plan Makes Stewardship and Access a Single Test

The Air We Breathe May Be Shaping the Future Burden of Blindness

Ozempic and Eye Health: Balancing Metabolic Benefits with Vision Risks
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
